Forecast how Ozempic, Wegovy, and Mounjaro reshape spirits volume. Big six guidance, earnings call commentary, and retail data are the resolution sources.
Every major spirits CEO now fields GLP-1 questions on earnings calls. The clinical data shows reduced alcohol intake among GLP-1 users, the consumer behavior is messier in aggregate, and the long-term volume impact is the most-debated number on Wall Street. These markets put a probability on the next twelve months of guidance and disclosure across Diageo, Pernod Ricard, Brown-Forman, Constellation, and Suntory.
Multiple peer-reviewed studies through 2024 and 2025 show that semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) reduce self-reported alcohol consumption among users by meaningful margins. The mechanism appears to act on reward pathways. The open question is how that translates to industry-level volume given prescription rates, adherence, and substitution.
Diageo, Pernod Ricard, Brown-Forman, Constellation Brands, and Anheuser-Busch InBev have all addressed GLP-1 questions on public earnings calls through fiscal 2025 and 2026. Most have framed the impact as long-term and not yet material. Liquor Bets runs markets on whether specific companies will explicitly cut volume guidance in connection with GLP-1 commentary in named reporting periods.